Market Size (2015)
2015
$86.00B
Healthcare
Renal Disease Market
By Segment, By Region, And Segment Forecasts, 2015 – 2023
Vertical: HealthcareBase Year: 201713 Sections
Executive Summary
Renal Disease Market — Snapshot
Projected (2023)
2023
$133.45B
CAGR (2015–2023)
5.6%
5.6%Key Players
110+
Renal diseases can be classified as chronic kidney disease (CKD) and end-stage renal disease (ESRD). When CKD worsens, it eventually leads to ESRD. The rising prevalence of kidney disease, diabetes, and hypertension and rapid growth in the geriatric population are driving the growth of the global renal disease market. However, rising healthcare costs and stringent regulatory policies may hamper market growth during the forecast period.
The global renal disease market is expected to register a CAGR of 6.32% during the forecast period of 2018 to 2023. In 2017, the market was led by the Americas with a 42.3% share, followed by Europe and Asia-Pacific with shares of 31.4% and 20.5%, respectively.
The global renal disease market has been segmented based on disease type, treatment type, end user, and region.
Based on disease type, the CKD segment accounted for the largest market share of 64.5% in 2017, with a market value of USD 60,228.68 million; it is projected to register a CAGR of 6.72% during the forecast period.
By treatment type, the dialysis segment accounted for the largest market share of 52.1% in 2017, with a market value of USD 48,625.55 million; it is projected to register a CAGR of 6.57% during the forecast period.
On the basis of end user, the dialysis centers segment accounted for the largest market share of 34.0% in 2017, with a market value of USD 31,737.35 million; it is projected to register a CAGR of 7.07% during the forecast period.
Key Insight
The Renal Disease Market market is projected to grow at a CAGR of 5.6% from 2015 to 2023.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Middle East and Africa, Americas, Asia Pacific, Europe.
- Market Segmentation: The market is analyzed across 2 segments: Chronic Kidney Disease, End-Stage Renal Disease (ESRD). Forecasts are provided for each segment from 2015 to 2023.
- Competitive Landscape: 110 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Renal Disease Market — Growth Trajectory
The scope of the global renal disease market study includes the market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on disease type, treatment type, end user, and region.
Research Objective
To provide a comprehensive analysis of the renal disease industry and its sub-segments in the global market, thereby providing a detailed structure of the industry To provide detailed insights into factors driving and restraining the growth of the global renal disease marketTo estimate the market size of the global renal disease market where 2015 to 2016 would be the historical period, 2017 shall be the base year, and 2018 to 2023 will be forecast period for the studyTo analyze the global renal disease market in four main geographies, namely, the Americas, Europe, Asia-Pacific, and the Middle East & AfricaTo provide country-wise market value analysis for various segments of the renal disease marketTo provide strategic profiling of key companies (manufacturers and distributors) present across the globe, and comprehensively analyze their competitiveness/competitive landscape in this marketTo provide a distribution chain analysis/value chain for the global renal disease market
Renal Disease Market — Growth Trajectory
Chronic Kidney Disease
End-Stage Renal Disease (ESRD)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Disease Type Disease Type is broken down into: Chronic Kidney Disease, End-Stage Renal Disease (ESRD).
- Treatment Type Treatment Type is broken down into: Dialysis, Medication, Kidney Transplantation.
- End User End User is broken down into: Dialysis Centres, Hospital & Clinics, Research and Academic Institutes, End User_Others.
Geographic Analysis
Regional market breakdown
- Middle East and Africa Middle East and Africa market size reached $5.25B in 2015 and is projected to reach $6.54B by 2023, growing at a CAGR of 2.8%.
- Americas Americas market size reached $36.23B in 2015 and is projected to reach $57.12B by 2023, growing at a CAGR of 5.9%.
- Asia Pacific Asia Pacific market size reached $17.14B in 2015 and is projected to reach $29.63B by 2023, growing at a CAGR of 7.1%.
- Europe Europe market size reached $27.38B in 2015 and is projected to reach $40.17B by 2023, growing at a CAGR of 4.9%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Renal Disease Market — How We Researched This Market
Research Process
Market Research Future analysis is based on interviews with industry experts who offer insight into the market structure, market segmentation, technology assessment, competitive landscape (CL), market penetration, as well as the emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and the current market position. Furthermore, the varying trends in segments and categories in each region are studied and estimated based on primary and secondary research.
Primary Research
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. For this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, marketing directors, and business development managers, among others) of the major players active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed in the next five years.
Secondary Research
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the global renal disease market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, geographical markets, and developments related to the market and technology. For this study, analysts have gathered information from various credible sources such as National Kidney Foundation, National Institute of Diabetes and Digestive and Kidney Disease, Centers for Disease Control and Prevention (CDC), Kidney Disease Statistics for the United States, European Renal Association, the Asian Pacific Society of Nephrology, Nephrology Dialysis Transplantation, World Health Organization (WHO), annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organizations of manufacturers, and paid databases.
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets of the overall global renal disease market. The key players in the market were identified through secondary research, and their market contributions in different applications across the globe were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis from Market Research Future added before being presented in this report. The following figure shows an illustrative representation of the overall market size estimation process employed for the purpose of this study.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Research Process
Historical data (2015–2017) and forecast period (2017–2023)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Renal Disease Market — Competitive Analysis
Bargaining Power of Suppliers
The bargaining power of suppliers in the global renal disease market is low to moderate. In this market, the suppliers are laboratory instruments and numerous drug manufacturers. There are many major and small manufacturers involved in providing various drugs and equipment that are used in clinical research, new drug development and for the treatment of diseases. Most of the major players are investing huge money in R&D and new product development. Innovation and advanced products give an edge to suppliers. Major brands have a strong presence and brand value in the market while many medium and small players are also providing the same products at different pricing. Grey market of products is affecting the bargaining power of suppliers. Quality of the products are the key factors that directly affect the bargaining power of suppliers. Moreover, the larger the number of suppliers in the market lower is the bargaining power of the supplier. The innovation and cost-effective products give an edge to suppliers to increase their market and create brand loyalty among the customer.
Bargaining Power of Buyers
The bargaining power of the buyer in the global renal disease market is high. Bargaining power of the buyer can define by a number of buyers, switching cost from one seller to other, and availability of alternative products. If the number of buyers for renal disease products is high the bargaining power will be low. There are different research centers, hospitals and academic industries using treatment devices, so the demand for the product is high. The presence of a large number of suppliers and low switching cost increases the bargaining power of the buyer. The threat of backward integration is low in this market.
Threat of New Entrants
The threat of new entrants in the global renal disease market is moderate. The global renal disease market is growing rapidly due to the growing geriatric population and the increasing number of sports injuries worldwide, rising R&D funding for the development of new diagnostic devices, increasing demand for dialysis by the hospitals. The companies involved in the mergers and acquisitions and rapid product launches are generating a huge amount of profit and influencing the potential companies to enter into this market.
The specialist knowledge or expertise related to product development and the huge capital required for the development of renal disease products acts as an entry barrier for the new players. Brand loyalty and tough competition from existing companies also prohibit the entry of new players.
Further, several small and medium-size companies are creating their space and trying to capture the market share which mostly untouched by major players. Easy distribution and undifferentiating product are increasing the threat of new entrants in the global renal disease market.
Threat of Substitutes
The threat of substitutes in the global renal disease market is low. The innovation and launch of new diagnostic & treatment systems for chronic kidney diseases (CKD) and other renal anomalies are increasing the threat of substitution for existing products. The customers tend to select the product according to their need and which provide the best results. The other factors that increase the threat of substitutes are low brand loyalty, increasing the price of the product and low switching cost. So, the companies are focusing on developing high-quality and cost-effective products as per the market need to decrease the threat of substitute.
Intensity of Rivalry
The intensity of rivalry in the global renal disease market is moderate. The rising demand for treatment techniques and diagnostic products by the end user such as hospitals and research academies are contributing to the increase in rivalry among the companies to capture a large market. Also, the increase in similar types of product offered by different companies increases the competition among the companies. The increase in the number of players decreases the profit share for each company and results to increase the intensity of competition in the respective market.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Renal Disease Market.
Regional Market Size (USD Mn)
Market estimates by geography (2023)
USD Mn
InsightAmericas leads with $57.12B by 2023, while Asia Pacific is projected to grow fastest at a 7.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $5.25B | $5.74B | $6.54B | 2.8% | 5% |
| Americas | $36.23B | $44.30B | $57.12B | 5.9% | 43% |
| Asia Pacific | $17.14B | $21.98B | $29.63B | 7.1% | 22% |
| Europe | $27.38B | $32.30B | $40.17B | 4.9% | 30% |
| Total | $86.00B | $104.32B | $133.45B | 5.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2023)
Chronic Kidney Disease
End-Stage Renal Disease (ESRD)
024218484367265496872
Segment Market Share
- Chronic Kidney Disease66%
- End-Stage Renal Disease (ESRD)34%
Total Market Size
$133.45B
Market by Segment (2023)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Chronic Kidney Disease | $88.06B | 5.6% | 40% |
| End-Stage Renal Disease (ESRD) | $45.39B | 5.6% | 89% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Renal Disease Market — Key Findings
Analytical insights on Renal Disease Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Renal Disease Market market is projected to reach $133.45B by 2023, growing at 5.6% CAGR. The Chronic Kidney Disease segment holds the largest share.
Market Drivers
Renal disease is also known as kidney disease. It occurs when the kidney cannot function properly. There are different types of kidney diseases. The renal disease could be caused due to numerous conditions and has different signs and symptoms depending upon how the conditions affect the kidneys. As per the survey conducted by the State Government of Victoria Australia in 2018, each year, more than 5,00,000 Australians consult their doctors about kidney disease and urinary tract infections. One in three Australian adults are at risk of developing chronic kidney disease, and one in ten has some signs of chronic kidney disease. Renal disease is also called as a silent disease because there are very few or no symptoms at all. According to a report published by the National Kidney Foundation in 2015, about 10% of the population worldwide are affected by chronic kidney disease (CKD) and millions die every year as they do not have access to affordable treatments. Over 2 million people worldwide receive treatment with dialysis or kidney transplant to stay alive. However, factors such as the rising prevalence of kidney disease, the growing prevalence of diabetes and hypertension, and rapid growth in the geriatric population may hamper the growth of the market during the forecast period.
Market Opportunities
Developing economies pose an opportunity for various markets as they have undeveloped research and development sectors owing to which they are unable to address upcoming health challenges. Despite huge demand, the African region is dependent on imported medicines and other health technologies. Although there is a high requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the African region. As per the statistics of WHO in 2017, around 90% of the population affected with renal disease lived in low- and middle-income countries. This huge population affected with the renal disease in developing countries serves as a strong opportunity for key players operating in the renal disease market.
Market Restraints
The prevalence of chronic kidney disease (CKD) among adults is about 15%. Around 30 million Americans may suffer from kidney disease, with millions of other Americans at risk. This is due to the rising prevalence of diabetes, hypertension, obesity, cardiovascular disease, and other conditions. Chronic kidney disease (CKD) has a high morbidity and mortality rate in developing countries. The high cost of medication and hemodialysis remains one of the major barriers in the successful treatment of CKD. As per the University of California San Francisco Survey, around 20,161 kidney transplants were performed in the US in 2016. The cost of the treatment increases exponentially with each progression stage of CKD. End-stage renal disease (ESRD) treatment costs even higher than chronic kidney disease. Furthermore, healthcare reengineering paradigms that manage increasing co-morbidities such as heart failure, diabetes, and hyperkalemia with advancing CKD, should offer additional potential for cost reductions in the coming years.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Market Value by Segment (2023)
Value (USD Mn)
Chronic Kidney Disease
End-Stage Renal Disease (ESRD)
Companies
Key companies profiled in Renal Disease Market
Profiles of 110 companies operating in the Renal Disease Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
BRISTOL-MY
BRISTOL-MYERS SQUIBB COMPANY
Healthcare
Company Headquarters: New York, US Founded: 1887 Workforce: ~28,000 Company Working: Bristol-Myers Squibb Company merged with Squibb in 1989. Bristol-Myers Squibb Company is a leading pharmaceutical company committed to develop and deliver innovative biopharmaceutical products to help patients fight diseases globally. It mainly focuses on six core therapeutic areas such as oncology, musculoskeletal, virology, cardiovascular, metabolomics, and immunology.
Revenue$16.6B
Employees28,000
Market CapN/A
Founded1886
New York, US
Fresenius
Fresenius
Healthcare
Company Headquarters: Hessen, Germany Founded: 1999 Workforce: 275,000 Company Working: Fresenius is a global healthcare company that operates through four business segments, such as Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Through its different business segments, the company offers its products and services for dialysis, clinical nutrition, infusion therapy, hospitals, and outpatient medical care. The company provides its services across 100 countries with its geographical presence in North America, Europe, Asia-Pacific, and Africa.
Revenue$31.4B
Employees275,000
Market CapN/A
Founded1998
Hessen, Germany
AstraZenec
AstraZeneca
Healthcare
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
Revenue$21.0B
Employees83,100
Market CapN/A
Founded1998
Cambridge, UK
Amgen Inc.
Amgen Inc.
Healthcare
Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.
Revenue$23.0B
Employees20,000
Market CapN/A
Founded1979
California, US
Teva Pharm
Teva Pharmaceutical Industries Ltd
Healthcare
Company Headquarters: Petah Tikva, Israel Founded: 1901 Workforce: 43,000+ Company Working: Teva Pharmaceutical Industries Ltd (Teva) is one of the leaders in pharmaceutical industries engaged in developing and providing services in generic medicines. The company has more than 1,800 molecules which are used to create an extensive variety of generic products in almost every therapeutic area. It is specialized in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics fields. It has more than 35,000 unique products, which is more than any other pharmaceutical company. Teva produced 120 billion tablets and capsules in 2017. Geographically, it operates in regions, namely, North America, Latin America, Europe, Japan, and South Korea. The company operates in more than 60 countries worldwide. It has 26 FDA approved plants, and 31 European Medicines Agency (EMA) approved plants worldwide.
Revenue$16.9B
Employees43,000
Market CapN/A
Founded1900
Petah Tikva, Israel
F. HOFFMAN
F. HOFFMANN-LA ROCHE LTD
Healthcare
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Revenue$63.3B
EmployeesN/A
Market CapN/A
FoundedN/A
United States, North America
Page 1 of 19
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Renal Disease Market
Starting from
$4,950